Multivariate OS analysis using Cox proportional hazards model (n = 58, 17 events)
| Parameter . | Hazard ratio . | 95% CI . | P value . | |
|---|---|---|---|---|
| Lower . | Upper . | |||
| Sex (male vs female) | 3.143 | 0.954 | 10.347 | .060 |
| Age (>10 vs ≤10 y) | 1.240 | 0.375 | 4.103 | .724 |
| Treatment era (lymphoid neoplasm diagnosis before 1 January 2000 vs after 1 January 2000) | 1.827 | 0.609 | 5.482 | .282 |
| Early (<1 y) vs late (≥1 y) since maintenance therapy initiation | 0.852 | 0.275 | 2.640 | .782 |
| Lymphoid neoplasm subtype (monomorphic LPD vs other) | 0.384 | 0.089 | 1.659 | .200 |
| CNS involvement (yes vs no) | 0.219 | 0.026 | 1.843 | .162 |
| Pulmonary involvement (yes vs no) | 1.729 | 0.492 | 6.077 | .393 |
| Concurrent HLH (yes vs no) | 7.318 | 1.624 | 32.978 | .010 |
| Parameter . | Hazard ratio . | 95% CI . | P value . | |
|---|---|---|---|---|
| Lower . | Upper . | |||
| Sex (male vs female) | 3.143 | 0.954 | 10.347 | .060 |
| Age (>10 vs ≤10 y) | 1.240 | 0.375 | 4.103 | .724 |
| Treatment era (lymphoid neoplasm diagnosis before 1 January 2000 vs after 1 January 2000) | 1.827 | 0.609 | 5.482 | .282 |
| Early (<1 y) vs late (≥1 y) since maintenance therapy initiation | 0.852 | 0.275 | 2.640 | .782 |
| Lymphoid neoplasm subtype (monomorphic LPD vs other) | 0.384 | 0.089 | 1.659 | .200 |
| CNS involvement (yes vs no) | 0.219 | 0.026 | 1.843 | .162 |
| Pulmonary involvement (yes vs no) | 1.729 | 0.492 | 6.077 | .393 |
| Concurrent HLH (yes vs no) | 7.318 | 1.624 | 32.978 | .010 |